Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D W FRY

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Journal of Medicinal Chemistry|December 16, 1997
Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorA M Thompson, D K Murray, W L Elliott, et al.
Journal of Medicinal Chemistry|February 16, 1996
Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorG W Rewcastle, B D Palmer, A J Bridges, et al.
Cancer Chemotherapy and Pharmacology|February 9, 2000
Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenograftsP W Vincent, A J Bridges, D J Dykes, et al.
Neoplasia (New York, N.Y.)|September 26, 2001
Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytesS W Stoll, S Kansra, S Peshick, et al.
Journal of Medicinal Chemistry|March 26, 1998
Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factorsG W Rewcastle, D K Murray, W L Elliott, et al.
Journal of Medicinal Chemistry|July 21, 2001
Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptorJ B Smaill, H D Showalter, H Zhou, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 30, 1998
Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitorD W Fry, A J Bridges, W A Denny, et al.
Journal of Medicinal Chemistry|February 14, 1997
Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congenersH D Showalter, A D Sercel, B M Leja, et al.
Journal of Medicinal Chemistry|May 29, 1999
Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptorJ B Smaill, B D Palmer, G W Rewcastle, et al.
Journal of Medicinal Chemistry|July 18, 1997
Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitorsJ M Hamby, C J Connolly, M C Schroeder, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Journal of Medicinal Chemistry|December 16, 1997
Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorA M Thompson, D K Murray, W L Elliott, et al.
Journal of Medicinal Chemistry|February 16, 1996
Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorG W Rewcastle, B D Palmer, A J Bridges, et al.
Cancer Chemotherapy and Pharmacology|February 9, 2000
Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenograftsP W Vincent, A J Bridges, D J Dykes, et al.
Neoplasia (New York, N.Y.)|September 26, 2001
Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytesS W Stoll, S Kansra, S Peshick, et al.
Journal of Medicinal Chemistry|March 26, 1998
Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factorsG W Rewcastle, D K Murray, W L Elliott, et al.
Journal of Medicinal Chemistry|July 21, 2001
Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptorJ B Smaill, H D Showalter, H Zhou, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 30, 1998
Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitorD W Fry, A J Bridges, W A Denny, et al.
Journal of Medicinal Chemistry|February 14, 1997
Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congenersH D Showalter, A D Sercel, B M Leja, et al.
Journal of Medicinal Chemistry|May 29, 1999
Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptorJ B Smaill, B D Palmer, G W Rewcastle, et al.
Journal of Medicinal Chemistry|July 18, 1997
Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitorsJ M Hamby, C J Connolly, M C Schroeder, et al.
Pageof 9